Targeted and Immune-Based Therapies for Acute Myeloid Leukemia: Inflammatory Signaling and Multiple Post-Translational Modifications.

Targeted and Immune-Based Therapies for Acute Myeloid Leukemia: Inflammatory Signaling and Multiple Post-Translational Modifications. Curr Med Chem. 2019;26(28):5242-5243 Authors: Selheim F PMID: 31721689 [PubMed - in process]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research

Related Links:

Conference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Conference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Conference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Condition:   AML Intervention:   Drug: MAX-40279-01 Sponsor:   Maxinovel Pty., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Interventions:   Drug: Decitabine;   Drug: Ponatinib;   Drug: Venetoclax Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   AML Intervention:   Drug: MAX-40279-01 Sponsor:   Maxinovel Pty., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Interventions:   Drug: Decitabine;   Drug: Ponatinib;   Drug: Venetoclax Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: C-A-E exhibited an inhibitory effect on AML cells by inducing mitochondrial apoptosis and promoting differentiation, both of which were highly correlated to the activation of ROS.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Authors: Wu S, Zhang W, Shen D, Lu J, Zhao L Abstract Phospholipase C (PLC) is a membrane-associated enzyme that regulates several cellular behaviors including cell motility, growth, transformation and differentiation. PLC is involved in cancer migration, invasion and drug resistance. However, the expression status and prognostic role of PLCB4 in acute myeloid leukemia (AML) remain unclear. In the present study, the complete clinical and mRNA expression data of 285 pediatric patients with de novo AML were obtained from the Therapeutically Available Research to Generate Effective Treatments database. The association...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation. Mol Med Rep. 2019 Nov 26;: Authors: Wang F, Li Z, Wang G, Tian X, Zhou J, Yu W, Fan Z, Dong L, Lu J, Xu J, Zhang W, Liang A Abstract Rearrangement of the mixed lineage leukemia (MLL; also known as lysine methyltransferase 2A) gene is a recurrent genomic aberration in acute myeloid leukemia (AML). MLLT3, super elongation complex subunit (AF9) is one of the most common MLL fusion partners in AML. The present study aimed to explore the aberrant expression of...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemistry | Leukemia